LifeNet Health LifeSciences is an innovative leader, trusted collaborator, and reliable solutions provider. We are committed to advancing science, accelerating discovery, and optimizing outcomes.
Leading the way in human in vitro biology, LifeSciences’ game-changing innovations, currently under development, include non-liver primary human cells.
Our primary cell pipeline consists of a diverse list of high-quality human primary cells. Stringent recovery, isolation, and characterization protocols are being developed and established specifically for each cell type. Lot specific documentation will include cell characterization data as well as comprehensive donor history.
New Cells to Aid Lung Disease Research
The newest primary cells being developed include three types of lung epithelial cells - alveolar type II, bronchial, and small airway. All three cell types show initial viability over 80% with appropriate morphology and cell marker expression. Continued development of these cells is a key initiative of 2021 due to their wide range of suitable applications focused on respiratory diseases, particularly SARS-CoV2 (the causative COVID-19 agent) infection studies and SARS disease modeling. We are actively seeking co-development partners. For more information, view our news release or use our Request More Info form.
Human Primary Cells in Development:
- Alveolar Type II Epithelial Cells
- Bronchial Epithelial Cells
- Small Airway Epithelial Cells
- Aortic Endothelial Cells
- Aortic Smooth Muscle Cells
- Dermal Fibroblasts
- Epidermal Keratinocytes
- Melanocytes
- Pancreatic Islet Cells
- Renal Proximal Tubule Epithelial Cells
- Thyrocytes
- Umbilical Cord Vascular Endothelial Cells
- Umbilical Mesenchymal Stem Cells
Learn More
Let’s work together. If you are interested in collaborating or partnering with LifeSciences to have access to our newest products entering beta-testing, such as non-liver primary cells or our Oncology Testing Services, please contact us.